Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T28141 |
Nek2-IN-5
NCL00017509 |
MAPK | MAPK |
Nek2-IN-5 (NCL00017509) 是一种具有有效性和选择性的 NIMA 相关激酶 2(Nek2)抑制剂。 | |||
T73287 |
Nek2-IN-6
|
||
Nek2-IN-6 是一种有效的 NIMA 相关激酶 2 (Nek2) 抑制剂。 | |||
T11960 |
MBM-55
|
GSK-3; MAPK; DYRK; Akt; Chk; Bcr-Abl; CDK; S6 Kinase; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; MAPK; PI3K/Akt/mTOR signaling; Stem Cells; Tyrosine Kinase/Adaptors |
MBM-55 是一种有效的中心体相关激酶 2 (NEK2) 抑制剂,IC50 为 1 nM。 MBM-55 通过诱导细胞周期停滞和凋亡有效抑制癌细胞的增殖。 | |||
T8216 |
T-1101 tosylate
TAI-95 tosylate |
Apoptosis; Microtubule Associated | Apoptosis; Cytoskeletal Signaling |
T-1101 tosylate (TAI-95 tosylate) 是一种具有抗肿瘤活性的 Hec1/Nek2抑制剂。 | |||
T11961 |
MBM-55S
|
GSK-3; MAPK; Akt; Bcr-Abl; CDK; S6 Kinase; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; MAPK; PI3K/Akt/mTOR signaling; Stem Cells; Tyrosine Kinase/Adaptors |
MBM-55S 是一种有效的 Nek2 抑制剂,IC50 为 1 nM。 MBM-55S 抑制细胞周期停滞和凋亡,从而抑制癌细胞的增殖。 MBM-55S 表现出抗肿瘤作用。 | |||
T11657 |
INH154
|
Others | Others |
INH154 是一种高效的 Nek2 和 Hec1 结合抑制剂,能够抑制 Hela 细胞(IC50:200 nM)、 MB468 细胞(IC50:120 nM)。 | |||
T6180 |
INH6
|
Apoptosis; Microtubule Associated | Apoptosis; Cytoskeletal Signaling |
INH6 是一种有效的 Hec1 抑制剂,可选择性地破坏 Hec1/Nek2 相互作用并诱导染色体错位。它抑制HeLa 细胞生长的IC50值为2.4 μM。 | |||
T6691 |
TAI-1
|
Apoptosis; Microtubule Associated | Apoptosis; Cytoskeletal Signaling |
TAI1 是一种具有口服活性的特异性 Hec1 抑制剂,有抗肿瘤活性,在 K562 细胞中的 GI50值为 13.48 nM。 | |||
T2502 |
INH1
IBT13131 |
Apoptosis; Microtubule Associated | Apoptosis; Cytoskeletal Signaling |
INH1 (IBT13131) 通过直接结合Hec1,特异性干扰 Hec1/Nek2 的相互作用。它在体内外均表现出良好的抗肿瘤活性。 | |||
T9880 |
ZINC05007751
|
MAPK | MAPK |
ZINC05007751 是 NIMA 相关激酶 NEK6 的有效抑制剂(IC50 = 3.4 μM)。 ZINC05007751 对 NEK1 和 NEK6 具有很强的特异性,对 NEK2、NEK7 和 NEK9 没有显着的活性。 | |||
T11958 | MBM-17 | Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
MBM-17 is a potent inhibitor of NIMA-related kinase 2 (Nek2,IC50 of 3 nM). It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. | |||
T11959 |
MBM-17S
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
MBM-17S, a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM, effectively inhibits cancer cell proliferation by inducing cell cycle arrest and apoptosis. It demonstrates antitumor activities without evident toxicity to mice. | |||
T28498 |
rac-CCT-250863
|
||
Rac-CCT-250863, a potent Nek2 inhibitor, exhibits selectivity for Nek2 over PLK1, MPS1, Cdk2 and Aurora A. | |||
T27052 |
CMP3a
CMP-3a,CMP 3a |
||
CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase E | |||
T38710 |
JH295
|
||
JH295 is a highly potent and selective inhibitor of NIMA-related kinase 2 (Nek2), exhibiting irreversible inhibition activity with an IC 50 value of 770 nM. This compound effectively inhibits cellular Nek2 using the alkylation of Cys22. Importantly, JH295 does not exhibit any inhibitory effects toward Cdk1, Aurora B, or Plk1, which are kinases involved in mitotic processes. Furthermore, JH295 has no impact on bipolar spindle assembly or the spindle assembly checkpoint mechanism. | |||
T24130 |
HCI-2184
HCI2184,HCI 2184 |
||
HCI-2184 is an inhibitor of AXL kinase and Nek2 that acts by successfully mitigating drug resistance in bortezomib-resistant multiple myeloma. | |||
T61061 | JH295 hydrate | ||
JH295 hydrate 通过 Cys22 烷基化从而抑制细胞Nek2,它是有效的,不可逆和选择性的NIMA 相关激酶 2 (Nek2)抑制剂 (IC50 = 770 nM)。JH295 hydrate 对有丝分裂激酶 Cdk1,Aurora B 或 Plk1 不具有活性,不干扰双极纺锤体组件或纺锤体组件检查点。 | |||
T81696 |
NBI-961
|
||
NBI-961为高效NEK2抑制剂,能阻断蛋白酶体降解作用。该化合物在弥漫性大B细胞淋巴瘤(DLBCL)细胞中诱导G2/有丝分裂停滞及细胞凋亡(apoptosis)。 | |||
T28498L |
rac-CCT-250863 HCl
rac-CCT-250863 HCl(1364269-06-6 Free base) |
Apoptosis | Apoptosis |
rac-CCT-250863 HCl 是一种具有选择性和可逆性的 NEK 2 抑制剂。rac-CCT-250863 HCl 能诱导细胞周期停滞,对癌细胞有较好的抗增殖活性,与 Pomalidomide 联用能诱导细胞凋亡,可用于联合抗癌的研究。 |